-
Despite Drug Trial Miss, Here's Why Biogen Should Trade Higher
Friday, December 9, 2016 - 2:18pm | 203Read More...BMO Capital Markets said Biogen Inc (NASDAQ: BIIB) shares should trade higher, despite a recent drug trial miss, on CTAD data (Clinical Trials on Alzheimer's Disease). The CTAD data show: “Solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (...
-
The Street Is Seeing Higher Probability Of Success For Incyte's Melanoma Treatment
Monday, October 10, 2016 - 12:08pm | 394Read More...BMO Capital’s M. Ian Somaiya expects higher probability of success for Incyte Corporation (NASDAQ: INCY)'s epacadostat+Keytruda trials in melanoma, given the PFS strength in the updated Phase I data presented at the meeting of the European Society for Medical Oncology. Somaiya maintains an...
-
Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?
Wednesday, September 9, 2015 - 2:22pm | 780Read More...Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) plunged nearly 80 percent on Wednesday, trading as low as $9.00 per share. The massive selloff is attributed to the company failing to meet the primary endpoint of statistical non-inferiority for IGNITE2 compared to levofloxacin. Here is a...
-
Biotech Investors: Nomura Says To Watch These Dates
Friday, April 10, 2015 - 1:10pm | 244Read More...Nomura commented on Gilead Sciences, Inc. (NASDAQ: GILD) and Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Friday. Analyst M. Ian Somaiya said that investors would be digesting competitive data from the European Association for the Study of Liver Disease (EASL) meeting on April 22-26 and would...
-
Analysts Respond To Pharmacyclics' Q4 Results
Thursday, February 19, 2015 - 3:25pm | 242Read More...Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 results on Wednesday and posted adjusted of EPS $0.96, above estimates of $0.76, on revenues of $290.2 million. The company also reaffirmed its fiscal 2015 outlook. JP Morgan analyst Cory Kasimov felt that the company’s long-term future...
-
Nomura Upgrades Pharmacyclics, Sees 'Upside' To Stock
Thursday, February 19, 2015 - 10:42am | 208Read More...Nomura upgraded Pharmacyclics, Inc. (NASDAQ: PCYC) Thursday from Neutral to Buy and raised it price target from $195 to $196. Analyst M. Ian Somaiya noted that the company reaffirmed its U.S. sales guidance of $1 billion on Wednesday and confirmed the analyst’s expectations for “off...
-
Nomura Just Cut Its Price Target On Gilead
Wednesday, February 4, 2015 - 11:56am | 297Read More...Want an edge on biotech stocks? Try this. Learn more about investing in the biotech sector with real-time trading picks from experts like the Biotech Trader. Nomura cut its price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $146 to $141 and maintained a Buy rating following the release...
-
Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical
Friday, January 16, 2015 - 4:34pm | 221Read More...BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) pipeline and existing products could drive a doubling of revenue every four years, an analyst said Friday. Nomura's M. Ian Somaiya boosted his target on the company by 6 percent to $123, maintaining a Buy rating and calling it his "top pick...
-
UPDATE: Piper Jaffray Upgrades Amgen Following Onyx Acquisition
Monday, August 26, 2013 - 10:28am | 178Read More...In a report published Monday, Piper Jaffray analyst M. Ian Somaiya upgraded the rating on Amgen (NASDAQ: AMGN) from Neutral to Overweight, and raised the price target from $120.00 to $140.00. In the report, Piper Jaffray noted, “We are upgrading AMGN to Overweight from Neutral and increasing our...
-
UPDATE: Piper Jaffray Initiates Onconova Therapeutics with Overweight on Multiple Positive Factors
Monday, August 19, 2013 - 10:38am | 197Read More...In a report published Monday, Piper Jaffray analyst M. Ian Somaiya initiated coverage on Onconova Therapeutics (NASDAQ: ONTX) with an Overweight rating and $38.00 price target. In the report, Piper Jaffray noted, “We are initiating coverage on Onconova with an Overweight rating and a 12-month...
-
UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors
Monday, July 1, 2013 - 11:34am | 165Read More...In a report published Monday, Piper Jaffray analyst M. Ian Somaiya reiterated a Neutral rating on Biogen Idec (NASDAQ: BIIB), and raised the price target from $229.00 to $251.00. In the report, Piper Jaffray noted, “We are increasing our Tecfidera sales estimates given the strength of the US...
-
Piper Jaffray Reiterates Overweight Rating on Incyte Following 3-Year Survival Data Presentation
Monday, June 17, 2013 - 12:21pm | 202Read More...In a report published Monday, Piper Jaffray analyst M. Ian Somaiya reiterated an Overweight rating and $27.00 price target on Incyte (NASDAQ: INCY). In the report, Piper Jaffray noted, “We reiterate our Overweight rating and $27 price target following the presentation of 3-year survival data...
-
Positive Results for Celgene's Revlimid (CELG)
Monday, June 14, 2010 - 8:28am | 92Read More...Updated results from Celgene's (NASDAQ: CELG) MM-015 study reaffirmed Revlimid's efficacy in improving progression free survival (PFS). The analysts said, "We believe that the data will support US and EU filing in front line MM. While US approval will likely have limited impact, as Revlimid is...
-
Piper Jaffray Raises BioMarin Pharmaceutical (BMRN) Price Target
Friday, April 30, 2010 - 9:23am | 162Read More...Piper Jaffray analysts M. Ian Somaiya and Sasha Blaug maintained their Neutral rating for shares of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), while raising the price target to $25 from the previous price target of $23. The analysts noted that BioMarin Pharmaceutical Inc released financial...
